Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication! Receive the the latest news, research, and presentations from major meetings ...

LONDON--(BUSINESS WIRE)--The report, heart defect closure devices market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and ...

A less invasive procedure for treating a congenital heart defect in children is a safe alternative to traditional surgery with no five-year difference in risk of death and is associated with a 62 ...